Table 3.
Multivariable-adjusted effect estimates for rs2486758 and biochemical response to abiraterone acetate and prednisone as well as time to biochemical progression in 87 patients with metastatic castration-resistant prostate cancer.
| Model | n | Response to Treatment | p |
|---|---|---|---|
| Unadjusted | 87 | OR 0.22 (0.07–0.63) | 0.005 |
| Age-adjusted (I) | 87 | OR 0.21 (0.07–0.62) | 0.005 |
| Multivariable-adjusted (II) | 87 | OR 0.22 (0.07–0.63) | 0.005 |
| Multivariable-adjusted (III) | 87 | OR 0.21 (0.07–0.62) | 0.005 |
| Multivariable-adjusted (IV) | 87 | OR 0.18 (0.06–0.57) | 0.003 |
| Time to Progression | |||
| Unadjusted | 87 | HR 2.23 (1.39–3.56) | <0.001 |
| Age-adjusted (I) | 87 | HR 2.22 (1.40–3.55) | 0.001 |
| Multivariable-adjusted (II) | 87 | HR 2.26 (1.41–3.62) | 0.001 |
| Multivariable-adjusted (III) | 87 | HR 2.29 (1.43–3.67) | 0.001 |
| Multivariable-adjusted (IV) | 87 | HR 2.67 (1.64–4.36) | <0.001 |
Effect estimates are expressed as unadjusted and multivariable-adjusted odds ratio (OR) (95% confidence interval) or hazard ratio (95% confidence interval) per minor allele. Model I was additionally adjusted for age at the time of abiraterone acetate initiation. Model II was additionally adjusted for Gleason score at the time of initial diagnosis. Model III was additionally adjusted for prostate-specific antigen at the time of abiraterone acetate initiation. Model IV was additionally adjusted for prior administration of docetaxel.